{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:38:01Z","timestamp":1758040681016,"version":"3.44.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.amjmed.2022.01.009","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T01:25:44Z","timestamp":1642901144000},"page":"S24-S29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["What Do the Elevated Protein Levels Mean in My Patients with Myeloma, Amyloidosis, and Related Disorders?"],"prefix":"10.1016","volume":"135","author":[{"given":"Scott R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Stockerl-Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjmed.2022.01.009_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.anai.2018.08.004","article-title":"Paraproteinemia and serum protein electrophoresis interpretation","volume":"122","author":"Raj","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"23","key":"10.1016\/j.amjmed.2022.01.009_bib0002","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2022.01.009_bib0003","doi-asserted-by":"crossref","unstructured":"Schroeder HW, Radbruch A, Berek C. B-cell development and differentiation. In: Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, eds. Clinical Immunology: Principles and Practice. 5th ed. London: Elsevier; 2019:107-118.","DOI":"10.1016\/B978-0-7020-6896-6.00007-7"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.009_bib0004","first-page":"105","article-title":"Understanding and interpreting serum protein electrophoresis","volume":"71","author":"O'Connell","year":"2005","journal-title":"Am Fam Physician"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.009_bib0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1515\/CCLM.2006.112","article-title":"Measurement of serum monoclonal components: comparison between densitometry and capillary zone electrophoresis","volume":"44","author":"Mussap","year":"2006","journal-title":"Clin Chem Lab Med"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.009_bib0006","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1515\/CCLM.2005.122","article-title":"Linearity and detection limit in the measurement of serum M-protein with the capillary zone electrophoresis system Capillarys","volume":"43","author":"Berg\u00f3n","year":"2005","journal-title":"Clin Chem Lab Med"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.009_bib0007","first-page":"1044","article-title":"Free light chain testing in follow-up of multiple myeloma","volume":"44","author":"Van Gysel","year":"2006","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.009_bib0008","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem"},{"issue":"1-2","key":"10.1016\/j.amjmed.2022.01.009_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1529-1049(02)00064-8","article-title":"Serum free light chain immunoassays and their clinical application","volume":"3","author":"Bradwell","year":"2002","journal-title":"Clin Appl Immunol Rev"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.009_bib0010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/2040620712466863","article-title":"Serum free light-chain assay for the detection and monitoring of multiple myeloma and related conditions","volume":"4","author":"Tosi","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.009_bib0011","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.009_bib0012","first-page":"131","article-title":"Quantitative serum free light chain assay\u2013analytical issues","volume":"30","author":"Tate","year":"2009","journal-title":"Clin Biochem Rev"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.009_bib0013","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1373\/clinchem.2004.046870","article-title":"Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice","volume":"51","author":"Katzmann","year":"2005","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.009_bib0014","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2022.01.009_bib0015","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated diagnostic criteria and staging system for multiple myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"12","key":"10.1016\/j.amjmed.2022.01.009_bib0016","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. [Internet]","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.amjmed.2022.01.009_bib0017","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.amjmed.2022.01.009_bib0018","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.amjmed.2022.01.009_bib0019","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1182\/blood-2013-08-520890","article-title":"Smoldering multiple myeloma requiring treatment: time for a new definition?","volume":"122","author":"Dispenzieri","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.009_bib0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM) [Internet]","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.009_bib0021","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1159\/000508287","article-title":"Prognosis and staging of AL amyloidosis","volume":"143","author":"Dittrich","year":"2020","journal-title":"Acta Haematol"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.009_bib0022","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.009_bib0023","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2017.1370421","article-title":"Attitudes about when and how to treat patients with AL amyloidosis: an international survey","volume":"24","author":"Milani","year":"2017","journal-title":"Amyloid"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.009_bib0024","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood-2017-04-780544","article-title":"Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies","volume":"131","author":"Palladini","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.009_bib0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1365-2141.2009.07807.x","article-title":"UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS) [Internet]","volume":"147","author":"Bird","year":"2009","journal-title":"Br J Haematol"},{"issue":"23","key":"10.1016\/j.amjmed.2022.01.009_bib0026","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1182\/blood-2014-08-551549","article-title":"How I treat smoldering multiple myeloma","volume":"124","author":"Ghobrial","year":"2014","journal-title":"Blood"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:26:05Z","timestamp":1757582765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322000328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":26,"alternative-id":["S0002934322000328"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.009","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Do the Elevated Protein Levels Mean in My Patients with Myeloma, Amyloidosis, and Related Disorders?","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}